Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

Neurol Neuroimmunol Neuroinflamm 2022;9:e200036. doi:10.1212/NXI.00000000000200036

In the Clinical/Scientific Note “Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod” by Palomares Cabeza et al.,1 the final name in Appendix 2 should be listed as “C.A.C.M. van Els.” The authors regret the error.

REFERENCE

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
Neurol Neuroimmunol Neuroinflamm 2022;9;
DOI 10.1212/NXI.000000000000200036

This information is current as of August 26, 2022

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/9/6/e200036.full.html

References
This article cites 1 articles, 1 of which you can access for free at:
http://nn.neurology.org/content/9/6/e200036.full.html##ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus